Literature DB >> 15944338

Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure.

Emmanuel Letavernier1, Joëlle Perez, Elisabeth Joye, Agnès Bellocq, Bruno Fouqueray, Jean-Philippe Haymann, Didier Heudes, Walter Wahli, Béatrice Desvergne, Laurent Baud.   

Abstract

Ischemic acute renal failure is characterized by damages to the proximal straight tubule in the outer medulla. Lesions include loss of polarity, shedding into the tubule lumen, and eventually necrotic or apoptotic death of epithelial cells. It was recently shown that peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases keratinocyte survival after an inflammatory reaction. Therefore, whether PPARbeta/delta could contribute also to the control of tubular epithelium death after renal ischemia/reperfusion was tested. It was found that PPARbeta/delta+/- and PPARbeta/delta-/- mutant mice exhibited much greater kidney dysfunction and injury than wild-type counterparts after a 30-min renal ischemia followed by a 36-h reperfusion. Conversely, wild-type mice that were given the specific PPARbeta/delta ligand L-165041 before renal ischemia were completely protected against renal dysfunction, as indicated by the lack of rise in serum creatinine and fractional excretion of Na+. This protective effect was accompanied by a significant reduction in medullary necrosis, apoptosis, and inflammation. On the basis of in vitro studies, PPARbeta/delta ligands seem to exert their role by activating the antiapoptotic Akt signaling pathway and, unexpectedly, by increasing the spreading of tubular epithelial cells, thus limiting potentially their shedding and anoikis. These results point to PPARbeta/delta as a remarkable new target for preconditioning strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944338     DOI: 10.1681/ASN.2004090802

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  40 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

3.  Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.

Authors:  Amandeep Bajwa; Sang-Kyung Jo; Hong Ye; Liping Huang; Krishna R Dondeti; Diane L Rosin; Volker H Haase; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2010-03-25       Impact factor: 10.121

4.  The role of nuclear receptors in the kidney in obesity and metabolic syndrome.

Authors:  Claudia Tovar-Palacio; Nimbe Torres; Andrea Diaz-Villaseñor; Armando R Tovar
Journal:  Genes Nutr       Date:  2012-04-25       Impact factor: 5.523

Review 5.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 6.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

7.  Role of PPARα and Its Agonist in Renal Diseases.

Authors:  Ching-Feng Cheng; Hsi-Hsien Chen; Heng Lin
Journal:  PPAR Res       Date:  2010-11-08       Impact factor: 4.964

Review 8.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

9.  PPAR-delta in Vascular Pathophysiology.

Authors:  Nanping Wang
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

10.  The PPARδ ligand GW501516 reduces growth but not apoptosis in mouse inner medullary collecting duct cells.

Authors:  Jordan Clark; Rania Nasrallah; Richard L Hébert
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.